 |
Linagliptin 'significantly lowers blood glucose'Phase III studies of Linagliptin, a compound being investigated by Boehringer Ingelheim as a once-daily oral treatment in type 2 diabetes, showed that the drug significantly lowered blood glucose, a report said. The drug, a dipeptidyl pept More… |
Tuesday 5 November 2024
